The incidence of melanoma has risen dramatically in recent years, but no therapy has improved overall survival for the majority of patients with unresectable metastatic disease. The University of Pittsburgh Cancer Institute (UPCI) Melanoma and Skin Cancer Program (MSCP) will continue to conduct a Specialized Program of Research Excellence (SPORE) to improve our understanding of molecular and immunologic mechanisms of cancer progression and to validate prognostic and predictive biomarkers for personalized treatment of advanced melanoma and cutaneous T cell lymphoma (CTCL). Of our 4 Projects, 1 is continued from the prior funding period, and 3 new projects have been derived from developmental research conducted in the last period;1 of the prior SPORE projects will be continued with independent ROI funding. Our highly integrated approach leverages complementary expertise in melanoma, oncology, dermatology, immunology, biostatistics, bioinformatics, machine learning, genomics, proteomics, and biomarker discovery to test hypotheses central to the improvement of therapeutic outcome in skin cancers. Regardless of clinical outcomes, these Projects will also generate urgently needed mechanistic data to inform development of new therapeutic strategies and pathways through which to monitor relapse and progression. Our 4 Projects will evaluate: (1) the prognostic and predictive value of the pro-inflammatory response and markers of immune suppression in relation to ipilimumab and interferon (IFN)? adjuvant therapy (leveraging an Eastern Cooperative Oncology Group-led adjuvant trial);(2) an engineered, 3-antigen dendritic cell vaccine and IFN? boost in patients with metastatic melanoma;(3) the safety and efficacy of vemurafenib modulation of immunotherapy with IFN?2b in patients with metastatic melanoma;and (4) an entirely new personalized microneedle vaccination technology in patients with melanoma and CTCL. The Administrative Core (A) coordinates the clinical research and provides scientific and fiscal oversight of the entire SPORE. The Biospecimen Core (B) is housed in the UPCI Immunologic Monitoring and Cellular Products Laboratory, where all tissue banking, biospecimen processing, and immune assays are conducted. The Biostatistics Core (C) and Informatics Core (D) support all projects with data analysis and management, respectively. We will continue to solicit, review, and fund applications for the career development and developmental research programs, which in the prior funding period led to the design of a new full project in this application (Project 3) and the promotion of career development recipients to co-investigators and a project leader.
The goal of this application is to use a multi-disciplinary approach to improve outcomes in skin cancer and in particular, metastatic melanoma, a disease with a 15% 5-year survival rate. We will improve treatment and outcomes for skin cancer patients by identifying new ways to treat the disease based on the biology of the individual patient's tumor and new biomarkers that predict risk and response to therapy to prevent recurrence based on an individual patient's genetics and the tumor impact upon the microenvironment.
|Retseck, Janet; VanderWeele, Robert; Lin, Hui-Min et al. (2016) Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer 4:38|
|Scharping, Nicole E; Menk, Ashley V; Moreci, Rebecca S et al. (2016) The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity 45:374-88|
|Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:|
|Bengsch, Bertram; Johnson, Andy L; Kurachi, Makoto et al. (2016) Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45:358-73|
|Sottile, Rosa; Pangigadde, Pradeepa N; Tan, Thomas et al. (2016) HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 46:409-19|
|Fan, Yiping; Lee, Seungjae; Wu, Gang et al. (2016) Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 136:339-42|
|Davar, Diwakar; Kirkwood, John M (2016) Adjuvant Therapy of Melanoma. Cancer Treat Res 167:181-208|
|Butterfield, Lisa H (2016) Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 65:805-12|
|Zarour, Hassane M (2016) Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res 22:1856-64|
|Blackler, Ryan J; Evans, Dylan W; Smith, David F et al. (2016) Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific mannerâ€ . Glycobiology 26:181-92|
Showing the most recent 10 out of 162 publications